InflaRx to Participate in Healthcare Innovation Conference
InflaRx N.V. (Nasdaq: IFRX), a leading biopharmaceutical company focused on groundbreaking anti-inflammatory treatments, has confirmed its participation in the upcoming Guggenheim Securities 2nd Annual Healthcare Innovation Conference. This significant event will take place from November 10 to November 12. On November 11, the company will host a fireside chat at 2:30 PM ET, providing insights into its innovative research and development.
Details of the Conference
The Guggenheim Securities conference serves as a crucial platform for InflaRx to engage with investors and share advancements in its therapeutic initiatives. During the event, InflaRx will also conduct one-on-one meetings with potential investors, facilitating deeper discussions on its strategic plans and innovations.
Live Streaming Options
For those interested in the developments at InflaRx, there will be a live stream available for the fireside chat. Attending virtually allows viewing the latest insights regarding anti-inflammatory therapies without geographic constraints.
Focus on Anti-Inflammatory Therapies
InflaRx is at the forefront of discovering and commercializing unique anti-inflammatory therapeutics, particularly by leveraging its proprietary technologies targeting the complement system. Their flagship product, vilobelimab, is an innovative drug developed to combat severe inflammatory responses. It works as a monoclonal antibody that specifically binds to C5a, a critical component in the inflammatory pathway, effectively inhibiting its function.
Recent Developments and Offerings
Beyond vilobelimab, InflaRx is advancing the development of INF904, an oral small molecule that inhibits C5a receptor signaling. These innovations play a vital role in addressing a spectrum of inflammatory conditions, highlighting InflaRx's commitment to enhancing patient outcomes.
About InflaRx N.V.
Founded in 2007, InflaRx has emerged as a leader in the biopharmaceutical landscape, focusing on targeting the complement system to address various inflammatory diseases. The company operates internationally, maintaining offices and subsidiaries in Jena and Munich, Germany, along with operations in Ann Arbor, MI. This diverse geographical spread mirrors its growing influence in the therapeutic area.
Contact Information
If you have inquiries about InflaRx, reach out to:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
What is the purpose of InflaRx's participation in the conference?
InflaRx aims to showcase its latest developments in anti-inflammatory therapeutics and engage with potential investors.
When will InflaRx’s fireside chat occur?
The fireside chat is scheduled for November 11 at 2:30 PM ET.
What are InflaRx’s main products?
InflaRx specializes in vilobelimab, a monoclonal antibody targeting C5a, and INF904, an oral small molecule inhibitor.
Where are InflaRx's offices located?
InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA.
How can I stream the fireside chat?
A link will be available for those interested to view the fireside chat live, offering insights into InflaRx's innovations.
